After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of CRISPR Therapeutics AG is $3.78B. A total of 2.49 million shares were traded on the day, compared to an average of 1.88M shares.
In the most recent transaction, Kulkarni Samarth sold 15,000 shares of CRSP for 55.10 per share on Dec 02 ’24. After the transaction, the Chief Executive Officer now owns 181,540 company shares. In a previous transaction on Nov 11 ’24, Kulkarni Samarth sold 30,000 shares at 55.62 per share. CRSP shares that Chief Executive Officer owns now total 196,540.
Among the insiders who sold shares, KASINGER JAMES R. disposed of 1,089 shares on Oct 14 ’24 at a per-share price of $46.28. This resulted in the General Counsel and Secretary holding 62,597 shares of CRSP after the transaction. In another insider transaction, Kulkarni Samarth sold 4,293 shares at $46.28 per share on Oct 14 ’24. Company shares held by the Chief Executive Officer now total 226,540.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CRSP has a high of $91.10 and a low of $36.52.
As of this writing, CRSP has an earnings estimate of -$1.18 per share for the current quarter. EPS was calculated based on a consensus of 22.0 estimates, with a high estimate of -$0.74 per share and a lower estimate of -$1.93.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CRSP’s latest balance sheet shows that the firm has $2.38B in Cash & Short Term Investments as of fiscal 2021. There were $225.03M in debt and $119.88M in liabilities at the time. Its Book Value Per Share was $22.73, while its Total Shareholder’s Equity was $2.40B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRSP is Buy with a score of 3.93.
